US stock · figures in US dollars · scored on full-year results
Henry Schein Henry Schein, Inc.
Henry Schein scores 35/100 on fundamentals: in the bottom 7% of 503 scored S&P 500 stocks. Its strongest area is Risk (58/100); its weakest is Price Fairness (0/100). It carries 1 warning flag: Weak Spot.
- Carries a Weak Spot flag
A financially stretched, expensively priced stock, but price fairness needs attention.
Nearby peers
Ranks #56 of 60 in Healthcare by score
One-Minute Summary
Why Henry Schein scores 35
A financially stretched, expensively priced stock, but price fairness needs attention.
Business Strength
30Why 30?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 10.2% over 4 years: customers keep spending more with this company.
Profit has moved sideways: stable, but not compounding your money faster each year.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 8.9% over the last 8 quarters: customers keep spending more with this company.
Profit has moved sideways over the last 8 quarters.
Financial Safety
33Why 33?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings grew about 39.1% over 4 years: watch this; rising debt adds pressure in bad times.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
50Why 50?
Show 3 charts
Operating vs Free Cash Flow
The business generates real cash, and more of it each year: a very healthy sign.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
0Why 0?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 34.3% over the past year.
Risk
58Why 58?
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Henry Schein (HSIC) scores 35/100 (Weak) on Score Your Stock's educational fundamentals model: in the bottom 7% of 503 scored S&P 500 stocks.
Its strongest pillar is Risk (58/100); its weakest is Price Fairness (0/100).
Henry Schein ranks #56 of 60 scored Healthcare stocks on Score Your Stock.
Henry Schein (HSIC) has not paid a dividend in the last 12 months.
On price alone, Henry Schein (HSIC) scores 0/100 (Weak) on Score Your Stock's Price Fairness pillar. Its P/E is 23.6×, so the price equals about 24 years of current profit. The pillar compares the share price with the company's profit, profit growth, assets and free cash, and its earnings yield with the government bond yield. A high score means the price looks cheap on these numbers; a low score means it looks expensive. It does not predict where the price goes next.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy HSIC. US shares trade one share at a time, not in lots of 100. Your broker will ask you to fill in a W-8BEN form, which tells the US you are not a US taxpayer. Malaysia has no income tax treaty with the US, so 30% of every dividend is withheld. Check the currency conversion fee too before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Henry Schein (HSIC) is a Healthcare company (Medical Distribution). On Score Your Stock's fundamentals check, it scores 35/100, rated Weak. Its biggest strength is Risk (58/100); its main watch-out is Price Fairness (0/100). Shares currently cost about 24 years of its current profit to buy (P/E 23.6×). Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/hsic-henry-schein
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Div yield | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 13.6b | US$ 403.0m | US$ 700.0m | US$ 513.0m | US$ -187.0m | US$ 157.0m | US$ 3.8b | US$ 1.2b | US$ 3.2b | US$ 4.6b | US$ 3.5b | US$ 11.4b | US$ 6.7b | US$ 2.1b | - | 13% | 3% | 1.2× | 1.3× | 4.5× | - | - | - |
| 2025 | US$ 13.2b | US$ 398.0m | US$ 712.0m | US$ 521.0m | US$ -191.0m | US$ 156.0m | US$ 3.4b | US$ 797.0m | US$ 3.2b | US$ 4.5b | US$ 3.2b | US$ 11.2b | US$ 6.4b | US$ 2.0b | US$ 0.0m | 12% | 3% | 1.1× | 1.4× | 4.6× | 0% | 22.4× | 2.7× |
| 2024 | US$ 12.7b | US$ 390.0m | US$ 848.0m | US$ 661.0m | US$ -187.0m | US$ 122.0m | US$ 2.9b | US$ 706.0m | US$ 3.4b | US$ 4.0b | US$ 2.8b | US$ 10.2b | US$ 5.4b | US$ 1.8b | US$ 0.0m | 11% | 3% | 0.9× | 1.4× | 4.9× | 0% | 22.0× | 2.5× |
| 2023 | US$ 12.3b | US$ 416.0m | US$ 500.0m | US$ 313.0m | US$ -187.0m | US$ 171.0m | US$ 2.7b | US$ 414.0m | US$ 3.7b | US$ 4.5b | US$ 2.7b | US$ 10.6b | US$ 5.4b | US$ 1.8b | US$ 0.0m | 11% | 3% | 0.8× | 1.7× | 7.2× | 0% | 23.5× | 2.7× |